RESUMO
PURPOSE: Evaluation of long-term outcome and toxicity of moderately hypofractionated radiotherapy using intensity-modulated radiotherapy (IMRT) with simultaneous integrated boost treatment planning and cone beam CT-based image guidance for localized prostate cancer. METHODS: Between 2005 and 2015, 346 consecutive patients with localized prostate cancer received primary radiotherapy using cone beam CT-based image-guided intensity-modulated radiotherapy (IG-IMRT) and volumetric modulated arc therapy (IG-VMAT) with a simultaneous integrated boost (SIB). Total doses of 73.9â¯Gy (nâ¯= 44) and 76.2â¯Gy (nâ¯= 302) to the high-dose PTV were delivered in 32 and 33 fractions, respectively. The low-dose PTV received a dose (D95) of 60.06â¯Gy in single doses of 1.82â¯Gy. The pelvic lymph nodes were treated in 91 high-risk patients to 45.5â¯Gy (D95). RESULTS: Median follow-up was 61.8 months. The 5year biochemical relapse-free survival (bRFS) was 85.4% for all patients and 93.3, 87.4, and 79.4% for low-, intermediate-, and high-risk disease, respectively. The 5year prostate cancer-specific survival (PSS) was 94.8% for all patients and 98.7, 98.9, 89.3% for low-, intermediate-, and high-risk disease, respectively. The 5year and 10-year overall survival rates were 83.8 and 66.3% and the 5year and 10-year freedom from distant metastasis rates were 92.2 and 88.0%, respectively. Cumulative 5year late GU toxicity and late GI toxicity grade ≥2 was observed in 26.3 and 12.1% of the patients, respectively. Cumulative 5year late grade 3 GU/GI toxicity occurred in 4.0/1.2%. CONCLUSION: Moderately hypofractionated radiotherapy using SIB treatment planning and cone beam CT image guidance resulted in high biochemical control and survival with low rates of late toxicity.